Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Journal of Substance Abuse Treatment

Volumn 34, Issue 1, 2008, Pages 61-71

  Green, Alan I ^a   Noordsy, Douglas L ^a   Brunette, Mary F ^a   O'Keefe, Christopher ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Atypical antipsychotics; Brain reward; Clozapine; Schizophrenia; Substance abuse

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CLOZAPINE; DISULFIRAM; DOPAMINE; HALOPERIDOL; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CARDIOMYOPATHY; CHOLESTEROL BLOOD LEVEL; COCAINE DEPENDENCE; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEUKOCYTE; LIVER TOXICITY; METABOLIC DISORDER; MOTOR DYSFUNCTION; NEUROBIOLOGY; NEUROLOGIC DISEASE; NONHUMAN; OPIATE ADDICTION; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RESPIRATION DEPRESSION; REWARD; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SUBSTANCE ABUSE; SYNCOPE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ALCOHOL DETERRENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISULFIRAM; DRUG INTERACTIONS; HUMANS; NALTREXONE; NARCOTICS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TAURINE;

EID: 36749055662     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2007.01.008     Document Type: Article

References (123)

1. Abram K.M., and Teplin L.A. Co-occurring disorders among mentally ill jail detainees. Implications for public policy. American Psychologist 46 (1991) 1036-1045
2. Addington J., and Addington D. Effect of substance misuse in early psychosis. British Journal of Psychiatry. Supplement 172 (1998) 134-136
3. Albanese M.J., Khantzian E.J., Murphy S.L., and Green A.I. Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry 151 (1994) 780-781
4. Alterman A.I., Ayre F.R., and Williford W.O. Diagnostic validation of conjoint schizophrenia and alcoholism. Journal of Clinical Psychiatry 45 (1984) 300-303
5. Batki S.L., Dimmock J., Cornell M., Wade M., Carey K., and Maisto S. Directly observed naltrexone treatment of alcohol dependence in schizophrenia: Preliminary analysis. Alcoholism, Clinical and Experimental Research 26 (2002) 83A
6. Bellack A.S., Bennett M.E., Gearon J.S., Brown C.H., and Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 63 (2006) 426-432
7. Beresford T.P., Clapp L., Martin B., Wiberg J.L., Alfers J., and Beresford H.F. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. Journal of Clinical Psychopharmacology 25 (2005) 363-366
8. Blanchard J.J., Brown S.A., Horan W.P., and Sherwood A.R. Substance use disorders in schizophrenia: Review, integration, and a proposed model. Clinical Psychology Review 20 (2000) 207-234
9. Bowers Jr. M.B., Mazure C.M., Nelson J.C., and Jatlow P.I. Psychotogenic drug use and neuroleptic response. Schizophrenia Bulletin 16 (1990) 81-85
10. Brady K.T., Anton R., Ballenger J.C., Lydiard R.B., Adinoff B., and Selander J. Cocaine abuse among schizophrenic patients. American Journal of Psychiatry 147 (1990) 1164-1167
11. Brady K.T., Sonne S.C., Anton R., and Ballenger J.C. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: A pilot study. Journal of Clinical Psychiatry 56 (1995) 118-121
12. Brown E.S., Jeffress J., Liggin J.D., Garza M., and Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. Journal of Clinical Psychiatry 66 (2005) 756-760
13. Brown E.S., Nejtec V.A., and Perantine D.C. Quetiapine in psychiatric illness with comorbid stimulant abuse. Paper presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, HI (2001, Dec 9-13)
14. Brunette M.F., Drake R.E., Lynde D., and IDDT Group. Toolkit for integrated dual disorders treatment (2002), Substance Abuse and Mental Health Services Administartion, Rockville, MD
15. Brunette M.F., Drake R.E., Xie H., McHugo G.J., and Green A.I. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin 32 (2006) 637-643
16. Brunette M.F., Mueser K.T., and Drake R.E. A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug and Alcohol Review 23 (2004) 471-481
17. Brunette M.F., Mueser K.T., Xie H., and Drake R.E. Relationships between symptoms of schizophrenia and substance abuse. Journal of Nervous and Mental Disease 185 (1997) 13-20
18. Buckley P.F. Substance abuse in schizophrenia: A review. Journal of Clinical Psychiatry 59 Suppl. 3 (1998) 26-30
19. Buckley P.F., McCarthy M., Chapman P., Richman C., and Yamamoto B. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophrenia Research 36 (1999) 272
20. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene × environment interaction. Biological Psychiatry 57 (2005) 1117-1127
21. Caton C.L., Shrout P.E., Eagle P.F., Opler L.A., and Felix A. Correlates of codisorders in homeless and never homeless indigent schizophrenic men. Psychological Medicine 24 (1994) 681-688
22. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2004. Morbidity and Mortality Weekly Report 54 (2005) 1121-1124
23. Chambers R.A., Krystal J.H., and Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 50 (2001) 71-83
24. Chengappa K.N., Vasile J., Levine J., Ulrich R., Baker R., Gopalani A., et al. Clozapine: Its impact on aggressive behavior among patients in a state psychiatric hospital. Schizophrenia Research 53 (2002) 1-6
25. Conley R.R., Kelly D.L., and Gale E.A. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophrenia Research 33 (1998) 95-101
26. Corrigan P.W., Reinke R.R., Landsberger S.A., Charate A., and Toombs G.A. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophrenia Research 63 (2003) 97-101
27. Cournos F., and McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: A critical review. Clinical Psychology Review 17 (1997) 259-269
28. Cruz H.A. Effectiveness of quetiapine in patients with dual diagnosis. Paper presented at the 25th National Conference on Correctional Health Care, Albuquerque, NM (2001 Nov 10-14)
29. Degenhardt L., Hall W., and Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence 71 (2003) 37-48
30. Dixon L., Haas G., Weiden P.J., Sweeney J., and Frances A.J. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry 148 (1991) 224-230
31. Drake R.E., and Brunette M.F. Complications of severe mental illness related to alcohol and other drug use disorders. In: Galanter M. (Ed). Recent developments in alcoholism: Consequences of alcoholism Vol. 14 (1998), Plenum Publishing Company, New York 285-299
32. Drake R.E., Essock S.M., Shaner A., Carey K.B., Minkoff K., Kola L., et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services 52 (2001) 469-476
33. Drake R.E., Mueser K.T., Brunette M.F., and McHugo G.J. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal 27 (2004) 360-374
34. Drake R.E., O'Neal E.L., and Wallach M.A. A systematic review of psychosocial interventions for people with co-occurring substance use and severe mental disorders. Journal of Substance Abuse Treatment 34 (2008) 123-138
35. Drake R.E., Osher F.C., and Wallach M.A. Alcohol use and abuse in schizophrenia. A prospective community study. Journal of Nervous and Mental Disease 177 (1989) 408-414
36. Drake R.E., Xie H., McHugo G.J., and Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin 26 (2000) 441-449
37. Drebing C.E., Van Ormer E.A., Krebs C., Rosenheck R., Rounsaville B., Herz L., et al. The impact of enhanced incentives on vocational rehabilitation outcomes for dually diagnosed veterans. Journal of Applied Behavior Analysis 38 (2005) 359-372
38. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 57 (2005) 594-608
39. Evins A.E., Cather C., Deckersbach T., Freudenreich O., Culhane M.A., Olm-Shipman C.M., et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology 25 (2005) 218-225
40. Farren C.K., Hameedi F.A., Rosen M.A., Woods S., Jatlow P., and Kosten T.R. Significant interaction between clozapine and cocaine in cocaine addicts. Drug and Alcohol Dependence 59 (2000) 153-163
41. Fowles D.C. Schizophrenia: Diathesis-stress revisited. Annual Review of Psychology 43 (1992) 303-336
42. George T.P., Sernyak M.J., Ziedonis D.M., and Woods S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry 56 (1995) 344-346
43. George T.P., Vessicchio J.C., Termine A., Bregartner T.A., Feingold A., Rounsaville B.J., et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 52 (2002) 53-61
44. George T.P., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 157 (2000) 1835-1842
45. Gonzalez V.M., Bradizza C.M., Vincent P.C., Stasiewicz P.R., and Paas N.D. Do individuals with a severe mental illness experience greater alcohol and drug-related problems? A test of the supersensitivity hypothesis. Addictive Behaviors 32 (2007) 477-490
46. Goodman L.A., Salyers M.P., Mueser K.T., Rosenberg S.D., Swartz M., Essock S.M., et al. Recent victimization in women and men with severe mental illness: Prevalence and correlates. Journal of Traumatic Stress 14 (2001) 615-632
47. Green A.I., Burgess E.S., Dawson R., Zimmet S.V., and Strous R.D. Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schizophrenia Research 60 (2003) 81-85
48. Green A.I., Chau D.T., Keung W.M., Dawson R., Mesholam R.I., and Schildkraut J.J. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research 128 (2004) 9-20
49. Green A.I., Salomon M.S., Brenner M.J., and Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Current Drug Targets. CNS and Neurological Disorders 1 (2002) 129-139
50. Green A.I., Zimmet S.V., Strous R.D., and Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard Review of Psychiatry 6 (1999) 287-296
51. Gupta S., Hendricks S., Kenkel A.M., Bhatia S.C., and Haffke E.A. Relapse in schizophrenia: Is there a relationship to substance abuse?. Schizophrenia Research 20 (1996) 153-156
52. Hiday V.A., Swartz M.S., Swanson J.W., Borum R., and Wagner H.R. Criminal victimization of persons with severe mental illness. Psychiatric Services 50 (1999) 62-68
53. Huguelet P., and Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacological Research 52 (2005) 392-394
54. Iber F.L., Lee K., Lacoursiere R., and Fuller R. Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics. Alcoholism, Clinical and Experimental Research 11 (1987) 301-304
55. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 361 (2003) 1677-1685
56. Kalyoncu A., Mirsal H., Pektas O., Unsalan N., Tan D., and Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: A potent anti-craving effect?. Journal of Psychopharmacology 19 (2005) 301-305
57. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63 (2002) 763-771
58. Khantzian E.J. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. American Journal of Psychiatry 142 (1985) 1259-1264
59. Khantzian E.J. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry 4 (1997) 231-244
60. Kingsbury S.J., and Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hospital & Community Psychiatry 41 (1990) 133-134
61. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter Jr. W.T., et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophrenia Research 20 (1996) 69-77
62. Kofoed L., Kania J., Walsh T., and Atkinson R.M. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. American Journal of Psychiatry 143 (1986) 867-872
63. Krakowski M.I., Czobor P., Citrome L., Bark N., and Cooper T.B. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63 (2006) 622-629
64. Krystal J.H., D'Souza D.C., Madonick S., and Petrakis I.L. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35 Suppl. (1999) S35-S49
65. Lee M.L., Dickson R.A., Campbell M., Oliphant J., Gretton H., and Dalby J.T. Clozapine and substance abuse in patients with schizophrenia. Canadian Journal of Psychiatry 43 (1998) 855-856
66. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
67. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 160 (2003) 1396-1404
68. Linszen D.H., Dingemans P.M., and Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51 (1994) 273-279
69. Littrell K.H., Petty R.G., Hilligoss N.M., Peabody C.D., and Johnson C.G. Olanzapine treatment for patients with schizophrenia and substance abuse. Journal of Substance Abuse Treatment 21 (2001) 217-221
70. Lysaker P., Bell M., Beam-Goulet J., and Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. Journal of Nervous and Mental Disease 182 (1994) 109-112
71. Marcus P., and Snyder R. Reduction of comorbid substance abuse with clozapine. American Journal of Psychiatry 152 (1995) 959
72. McEvoy J.P., Freudenreich O., Levin E.D., and Rose J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 119 (1995) 124-126
73. McEvoy J.P., Freudenreich O., and Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological Psychiatry 46 (1999) 125-129
74. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163 (2006) 600-610
75. Meltzer H.Y. Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options. Current Psychiatry Reports 4 (2002) 279-283
76. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60 (2003) 82-91
77. Miotto P., Preti A., and Frezza M. Heroin and schizophrenia: Subjective responses to abused drugs in dually diagnosed patients. Journal of Clinical Psychopharmacology 21 (2001) 111-113
78. Mueser K.T., Aalto S., Becker D.R., Ogden J.S., Wolfe R.S., Schiavo D., et al. The effectiveness of skills training for improving outcomes in supported employment. Psychiatric Services 56 (2005) 1254-1260
79. Mueser K.T., Noordsy D., Drake R.E., and Fox M. Integrated treatment for dual disorders: A guide to effective practice (2003), The Guilford Press, New York
80. Mueser K.T., Yarnold P.R., Levinson D.F., Singh H., Bellack A.S., Kee K., et al. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin 16 (1990) 31-56
81. Noordsy D.L., O'Keefe C., Mueser K.T., and Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatric Services 52 (2001) 501-507
82. Noordsy D.L., O'Keefe C., Mueser K.T., and Xie H. Switching to olanzapine in naturalistic community care. Paper presented at the 154th Annual Meeting of the American Psychiatric Association (2001)
83. Noordsy D.L., Torrey W.C., Mead S., Brunette M.F., Potenza D., and Copeland M.E. Recovery-oriented psychopharmacology: Redefining the goals of antipsychotic treatment. Journal of Clinical Psychiatry 61 Suppl. 3 (2000) 22-29
84. Owen R.R., Fischer E.P., Booth B.M., and Cuffel B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services 47 (1996) 853-858
85. Petrakis I.L., Leslie D., Finney J.W., and Rosenheck R. Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. American Journal on Addictions 15 (2006) 44-49
86. Petrakis I.L., Nich C., and Ralevski E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bulletin 32 (2006) 644-654
87. Petrakis I.L., O'Malley S., Rounsaville B., Poling J., McHugh-Strong C., and Krystal J.H. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 172 (2004) 291-297
88. Potvin S., Pampoulova T., Mancini-Marie A., Lipp O., Bouchard R.H., and Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology, Neurosurgery, and Psychiatry 77 (2006) 796-798
89. Potvin S., Stip E., Lipp O., Elie R., Mancini-Marie A., Demers M.F., et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial. Current Medical Research and Opinion 22 (2006) 1277-1285
90. Potvin S., Stip E., and Roy J.Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: Towards testable hypotheses. International Clinical Psychopharmacology 18 (2003) 121-132
91. Potvin S., Stip E., and Roy J.Y. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Canadian Journal of Psychiatry 49 (2004) 711
92. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. [comment]. Journal of the American Medical Association 264 (1990) 2511-2518
93. Richard M.L., Liskow B.I., and Perry P.J. Recent psychostimulant use in hospitalized schizophrenics. Journal of Clinical Psychiatry 46 (1985) 79-83
94. Ries R.K., Dyck D.G., Short R., Srebnik D., Fisher A., and Comtois K.A. Outcomes of managing disability benefits among patients with substance dependence and severe mental illness. Psychiatric Services 55 (2004) 445-447
95. Rosenberg S.D., Goodman L.A., Osher F.C., Swartz M.S., Essock S.M., Butterfield M.I., et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health 91 (2001) 31-37
96. Rsenberg S.D., Trumbetta S.L., Mueser K.T., Goodman L.A., Osher F.C., Vidaver R.M., et al. Determinants of risk behavior for human immunodeficiency virus/acquired immunodeficiency syndrome in people with severe mental illness. Comprehensive Psychiatry 42 (2001) 263-271
97. Roth R.M., Brunette M.F., and Green A.I. Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?. Current Psychiatry Reports 7 (2005) 283-291
98. Rubio G., Martinez I., Ponce G., Jimenez-Arriero M.A., Lopez-Munoz F., and Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry 51 (2006) 531-539
99. Salloum I.M., Cornelius J.R., Daley D.C., Kirisci L., Himmelhoch J.M., and Thase M.E. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Archives of General Psychiatry 62 (2005) 37-45
100. Salyers M.P., and Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 48 (2001) 109-123
101. Sayers S.L., Campbell E.C., Kondrich J., Mann S.C., Cornish J., O'Brien C., et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. Journal of Nervous and Mental Disease 193 (2005) 379-386
102. Scheller-Gilkey G., Thomas S.M., Woolwine B.J., and Miller A.H. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophrenia Bulletin 28 (2002) 223-231
103. Siris S.G. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bulletin 16 (1990) 111-122
104. Siris S.G., Mason S.E., Bermanzohn P.C., Shuwall M.A., and Aseniero M.A. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacology Bulletin 29 (1993) 127-133
105. Smelson D.A., Losonczy M.F., Davis C.W., Kaune M., Williams J., and Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry 47 (2002) 671-675
106. Smelson D.A., Ziedonis D., Williams J., Losonczy M.F., Williams J., Steinberg M.L., et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. Journal of Clinical Psychopharmacology 26 (2006) 9-12
107. Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behaviour. British Journal of Psychiatry 176 (2000) 345-350
108. Stroup T.S., Kraus J.E., and Marder S.R. Pharmacotherapies. In: Lieberman J.A., Stroup T.S., and Perkins D.O. (Eds). Textbook of schizophrenia (2006), American Psychiatric Publishing, Washington, DC 303-325
109. Svensson T.H., Mathe J.M., Andersson J.L., Nomikos G.G., Hildebrand B.E., and Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. Journal of Clinical Psychopharmacology 15 1 Suppl. 1 (1995) 11S-18S
110. Swanson J.W., Holzer III C.E., Ganju V.K., and Jono R.T. Violence and psychiatric disorder in the community: Evidence from the Epidemiologic Catchment Area surveys. Hospital & Community Psychiatry 41 (1990) 761-770
111. Swanson J.W., Swartz M.S., Van Dorn R.A., Elbogen E.B., Wagner H.R., Rosenheck R.A., et al. A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 63 (2006) 490-499
112. Swartz M.S., Wagner H.R., Swanson J.W., Stroup T.S., McEvoy J.P., Canive J.M., et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 194 (2006) 164-172
113. Treffert D.A. Marijuana use in schizophrenia: A clear hazard. American Journal of Psychiatry 135 (1978) 1213-1215
114. Tsuang M.T., Simpson J.C., and Kronfol Z. Subtypes of drug abuse with psychosis. Demographic characteristics, clinical features, and family history. Archives of General Psychiatry 39 (1982) 141-147
115. Volavka J., Zito J.M., Vitrai J., and Czobar P. Clozapine effects on hostility and aggression in schizophrenia. Journal of Clinical Psychopharmacology 13 (1993) 287-289
116. Walker E.F., and Diforio D. Schizophrenia: A neural diathesis-stress model. Psychological Review 104 (1997) 667-685
117. Warsi M., Sattar S.P., Bhatia S.C., and Petty F. Aripiprazole reduces alcohol use. Canadian Journal of Psychiatry 50 (2005) 244
118. Weiss R.D., Griffin M.L., Kolodziej M.E., Greenfield S.F., Najavits L.M., and Daley D.C. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. American Journal of Psychiatry 164 (2007) 100-107
119. Weller M.P., Ang P.C., Latimer-Sayer D.T., and Zachary A. Drug abuse and mental illness. Lancet 1 (1988) 997
120. Yovell Y., and Opler L.A. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: A case report and a hypothesis. Journal of Nervous and Mental Disease 182 (1994) 591-592
121. Ziedonis D.M., Richardson T., Lee E., Petrakis I., and Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacology Bulletin 28 (1992) 309-314
122. Ziedonis D.M., Smelson D., Rosenthal R.N., Batki S.L., Green A.I., Henry R.J., et al. Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. Journal of Psychiatric Practice 11 (2005) 315-339
123. Zimmet S.V., Strous R.D., Burgess E.S., Kohnstamm S., and Green A.I. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. Journal of Clinical Psychopharmacology 20 (2000) 94-98